Investor Presentaiton
Investor presentation
Full year 2018
Slide 61
Stable insulin leadership position in Region AAMEO
Region AAMEO insulin market by segment
Region AAMEO modern and new-generation
insulin volume market shares
tMU
120
100
80
60
40
20
0
Nov
2013
-
Device penetration
-
MI and NGI penetration
Penetration
CAGR volume¹: 7.5%
CAGR value¹:
4.1%
100%
70%
60%
80%
Fast-acting
50%
60%
40%
Premix
30%
40%
20%
20%
Long-acting
10%
0%
0%
Nov
2018
Nov
2013
-
Novo Nordisk
1 CAGR for 5-year period.
Note: IQVIA only covers the following 8 markets in AAMEO (retail data): Algeria, Egypt, India, New
Zealand, Russia, Saudi Arabia, South Africa and Turkey, which together accounts for 82% of Novo Nordisk
insulin sales in region AAMEO
Source: IQVIA monthly MAT Nov, 2018 volume and value figures
AAMEO: Africa, Asia, the Middle-East and Oceania; MI: Modern insulin; NGI: New-generation insulin
Source: IQVIA monthly MAT Nov, 2018 volume figures
Sanofi
Eli Lilly
Other
57%
20%
13%
10%
Nov
2018
novo nordiskView entire presentation